CD274 and neoplasm: Studies have shown that immune checkpoint inhibitors (ICI) response is seen in 50% patients with high tumor mutation burden, Programmed cell death ligand-1 (PD-L1) expression, and infiltration by cytotoxic T-cells without significant difference among different molecular subtypes, questioning clinical utility of molecular subtypes [14, 15].